Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
LRMR Larimar Therapeutics
- 6.170
- +0.060+0.98%
Close Dec 13 16:00 ET
- 6.170
- 0.0000.00%
Post 19:59 ET
393.69MMarket Cap-5.37P/E (TTM)
6.307High6.010Low436.14KVolume6.200Open6.110Pre Close2.68MTurnover1.38%Turnover RatioLossP/E (Static)63.81MShares13.68052wk High1.98P/B195.08MFloat Cap3.79552wk Low--Dividend TTM31.62MShs Float664.320Historical High--Div YieldTTM4.85%Amplitude1.530Historical Low6.153Avg Price1Lot Size
Larimar Therapeutics News
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Blue Owl Capital Holdings LP(6.53%)
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(8.7%),Janus Henderson Biotech Innovation Master Fund Ltd(7.5%)
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Verition Fund Management LLC(0.9%),Nicholas Maounis(0.9%)
Larimar Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-THE GOLDMAN SACHS GROUP, INC.(7.0 %),GOLDMAN SACHS & CO. LLC(7.0 %)
Larimar Therapeutics | 10-Q: Q3 2024 Earnings Report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 10-Q: Q2 2024 Earnings Report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Flynn James E
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hamilton Thomas Edward
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Truitt Joseph
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SHERMAN JEFFREY W
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director LEFF JONATHAN S
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director THOMAS FRANK E
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | EFFECT: Others
Larimar Therapeutics | CORRESP: CORRESP
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.